Valinor is an AI-driven biotechnology company building multimodal machine-learning models trained on matched multi-omic and clinical outcome datasets to predict patient response to therapeutics. Its platform enables drug developers to distinguish responders from non-responders, refine target populations, and uncover novel biology that can reveal new indications. The company’s proprietary datasets combine patient-derived omics data with real-world treatment outcomes, providing a rich foundation for predictive modeling across multiple disease areas. Valinor operates on an AI-first, disease-focused approach designed to reduce R&D costs, de-risk drug development, and shorten time to market for life-saving medicines. With fresh capital, the team plans to expand its dataset library, hire additional machine-learning talent, and deepen collaborations with pharmaceutical partners. Although revenue or user figures were not disclosed, the seed financing underscores investor confidence in the platform’s commercial potential. The company is headquartered in San Francisco and is actively seeking collaborations for customized patient-selection models.

Total raised

$13M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2025